Mirtazapina Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral administration. It is prescribed to manage major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global healthcare providers.

Mirtazapine acts on the central noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adults.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Hepatic dysfunction - Leukopenia

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Psychiatric assessment: monitor for worsening depression or emergent suicidal ideation - Hepatic function: use with caution in patients with severe liver impairment - Cardiovascular status: observe blood pressure in hypertensive individuals - Discontinuation: avoid abrupt cessation; taper under medical supervision - Pregnancy and lactation: prescribe only if benefits outweigh potential risks - Store at ambient temperature: keep in the original container, protect from moisture and light

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels - Central nervous system depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive dry‑mouth effects - Other serotonergic drugs (e.g., tramadol, triptans): potential serotonin syndrome - Warfarin: possible increase in INR, requiring coagulation monitoring